why choose us

First received: September 01, 2023

Clinical Trial: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Ulcerative Colitis

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis

Brief Summary: The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis.The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo.The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.

Read more